Company intelligence / Profile preview

Hwa-In Group

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Hwa-In Group is a South Korean healthcare conglomerate primarily focused on the manufacturing, distribution, and development of pharmaceutical products. The group operates through several subsidiaries, including Hwa-In Pharmaceutical, which handles traditional chemical drugs, and Hwa-In Bio, which focuses on biotechnological advancements and biosimilars. They are known for providing a wide range of therapeutic solutions in the Korean domestic market and have established a presence in international trade. The company emphasizes quality control and has expanded its capabilities into R&D for innovative therapies and generic formulations.

Therapeutic areas: CardiovascularRheumatologyGastroenterologyMetabolic Disorders
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Hwa-In Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hwa-In Group.

Explore the full profile